{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:58:12Z","timestamp":1769507892042,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ejphar.2014.01.028","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T08:30:24Z","timestamp":1390984224000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells"],"prefix":"10.1016","volume":"727","author":[{"given":"Mar\u00eda Laura","family":"Sbaraglini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Silvina","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sedlinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le\u00f3n","family":"Schurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Desmond","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.01.028_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14740338.2013.741584","article-title":"Saxagliptin overview: special focus on safety and adverse effects","volume":"12","author":"Ali","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2014.01.028_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1534734611400256","article-title":"The diabetic bone: a cellular and molecular perspective","volume":"10","author":"Blakytny","year":"2011","journal-title":"Int. J. Low. Extrem. Wounds"},{"key":"10.1016\/j.ejphar.2014.01.028_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jcb.10369","article-title":"Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways","volume":"88","author":"Franceschi","year":"2003","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.ejphar.2014.01.028_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bone.2011.06.018","article-title":"Novel functions for insulin in bone","volume":"50","author":"Fulzele","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2014.01.028_bib5","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/dmd.108.026088","article-title":"Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections","volume":"37","author":"Fura","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2014.01.028_bib6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1517\/14656566.9.9.1495","article-title":"New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin","volume":"9","author":"Gagliardino","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2014.01.028_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.diabres.2010.07.006","article-title":"DPP-4 inhibitors: what may be the clinical differentiators?","volume":"90","author":"Gerich","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2014.01.028_bib8","series-title":"D.C","article-title":"Committee for the Update of the Guide for the Care and Use of Laboratory Animals; Institute for Laboratory Animal Research; Division on Earth and Life Studies, National Research Council of The National Academies","author":"Guide","year":"2011"},{"key":"10.1016\/j.ejphar.2014.01.028_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","article-title":"Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture","volume":"166","author":"Janghorbani","year":"2007","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ejphar.2014.01.028_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/0-306-46826-3_14","article-title":"Signal transduction events induced or affected by inhibition of the catalytic activity of dipeptidyl peptidase IV (DPP IV, CD26)","volume":"477","author":"Kahne","year":"2000","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2014.01.028_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbrc.2008.08.034","article-title":"Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression","volume":"375","author":"Kanazawa","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2014.01.028_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/en.2010-1098","article-title":"Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice","volume":"152","author":"Kyle","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2014.01.028_bib13","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2174\/092986709788803114","article-title":"Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme","volume":"16","author":"Matteucci","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2014.01.028_bib14","first-page":"6","article-title":"AGEs and bone ageing in Diabetes mellitus","volume":"4","author":"McCarthy","year":"2013","journal-title":"J. Diabetes Metab."},{"key":"10.1016\/j.ejphar.2014.01.028_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.numecd.2010.07.008","article-title":"Mechanisms of impaired bone strength in type 1 and 2 diabetes","volume":"20","author":"Merlotti","year":"2010","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.ejphar.2014.01.028_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1359\/jbmr.090732","article-title":"Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies","volume":"25","author":"Molinuevo","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejphar.2014.01.028_bib17","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","article-title":"Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials","volume":"34","author":"Monami","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2014.01.028_bib18","unstructured":"Onglyza\u00ae, s.p.i.D.B.-M.S., 2011. Onglyza\u00ae (saxagliptin) package insert, 2011 December. Bristol-Myers Squibb (packageinserts.bms.com\/pi\/pi_onglyza.pdf)."},{"key":"10.1016\/j.ejphar.2014.01.028_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/en.2003-0746","article-title":"Bone is a target for the antidiabetic compound rosiglitazone","volume":"145","author":"Rzonca","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2014.01.028_bib20","article-title":"The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes","volume":"44","author":"Schon","year":"1985","journal-title":"Biomed. Biochim. Acta"},{"key":"10.1016\/j.ejphar.2014.01.028_bib21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with Type 2 Diabetes Mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2014.01.028_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejphar.2011.07.033","article-title":"Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats","volume":"668","author":"Sedlinsky","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.01.028_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1359\/JBMR.051004","article-title":"Immunocompetent properties of human osteoblasts: interactions with T lymphocytes","volume":"21","author":"Stanley","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejphar.2014.01.028_bib24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S1734-1140(09)70147-1","article-title":"Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors","volume":"61","author":"Tahara","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2014.01.028_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrm1837","article-title":"Critical nodes in signalling pathways: insights into insulin action","volume":"7","author":"Taniguchi","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2014.01.028_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.jid.5701104","article-title":"Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts","volume":"128","author":"Thielitz","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2014.01.028_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/cbf.1668","article-title":"Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells","volume":"28","author":"Yang","year":"2010","journal-title":"Cell Biochem. Funct."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T01:58:26Z","timestamp":1538877506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":27,"alternative-id":["S0014299914000478"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.028","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}